Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) Participants

Sponsor
GlaxoSmithKline
Study ID
NCT04657211
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Prospective observational cohort study — OTHER
    prospective observational cohort study

Study Details

TETRIS is a multi-center, prospective observational cohort study. It will include participants with COPD who are on an existing combined treatment of long-acting muscarinic antagonist (LAMA), long-acting beta 2 agonists (LABA) and inhaled corticosteroids (ICS).

Key Dates

First listed
Dec 8, 2020
Start date
Jan 14, 2021
Status verified
Aug 2025
Primary completion
Jul 1, 2024
Completion
Jul 1, 2024

Study Design

Enrollment
1,212 participants (actual)

Arms

  • Arm: Participants with chronic obstructive pulmonary disease (COPD)
    Participants with COPD, who will be treated with triple therapy (single inhaler triple therapy \[SITT\] or multiple inhaler triple therapy \[MITT\]) for at least 2 but not longer than 48 weeks will be enrolled in this study. No study treatment will be administered during conduct of this study.

Primary Outcome Measure

Percentage of Participants Who Continuously Received Triple Therapy for 6 Months [ Time Frame: From Day 1 (Month 1) up to 6 months ]

Find similar trials

Nationwide
COPD trialsPulmonology trialsLung disease trials

Related Studies